Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$0.78
-2.3%
$1.22
$0.73
$3.94
$154.70M0.755.50 million shs5.92 million shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.13
+2.3%
$14.08
$5.22
$27.38
$152.69M0.41138,991 shs131,527 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.01
-1.0%
$3.09
$2.23
$5.20
$149.39M1.29440,856 shs310,742 shs
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
$11.24
$0.87
$2.72
$37.57M1.161.04 million shs9,405 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-2.28%-19.97%-23.46%-58.47%-64.99%
LifeVantage Co. stock logo
LFVN
LifeVantage
+2.28%+1.08%-14.21%-37.35%+79.17%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-0.99%+1.01%+6.74%+7.89%-41.38%
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
0.00%0.00%0.00%0.00%+38.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
3.57 of 5 stars
3.32.00.03.91.51.70.6
LifeVantage Co. stock logo
LFVN
LifeVantage
3.9946 of 5 stars
3.51.01.72.72.21.71.3
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.7938 of 5 stars
3.51.00.00.02.73.33.1
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.50
Moderate Buy$6.25700.56% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50151.44% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00132.56% Upside
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTI, ESPR, LFVN, and PBYI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.00
4/8/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/20/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/4/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
2/28/2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$259.57M0.60N/AN/A($3.85) per share-0.20
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.69$0.64 per share19.03$2.38 per share5.10
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.47M0.65$0.72 per share4.19$1.12 per share2.69
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
$5M0.00N/AN/A$1.22 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$209.25M-$0.80N/AN/AN/A-29.37%N/A-10.77%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6921.66N/A3.46%34.29%15.04%N/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$21.59M$0.776.277.92N/A9.56%41.60%10.71%N/A
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
-$59.13M-$1.16N/AN/AN/AN/A-75.39%-55.04%N/A

Latest PTI, ESPR, LFVN, and PBYI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
2/27/2025Q4 2024
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.10$0.39+$0.29$0.39$52.50 million$59.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.48%N/A26.09%2 Years
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
N/AN/AN/AN/AN/A

Latest PTI, ESPR, LFVN, and PBYI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.85
1.37
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.46
1.42
1.40
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
N/A
6.69
6.69

Institutional Ownership

CompanyInstitutional Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
16.64%

Insider Ownership

CompanyInsider Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.00%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.70%
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.15 million195.07 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million37.45 millionOptionable
Proteostasis Therapeutics, Inc. stock logo
PTI
Proteostasis Therapeutics
4452.19 millionN/ANot Optionable

Recent News About These Companies

News From PTI
Qureshi barred, many PTI leaders cleared to contest polls
PTI core committee urges ECP to allocate ‘bat’ symbol

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$0.78 -0.02 (-2.28%)
Closing price 05/13/2025 04:00 PM Eastern
Extended Trading
$0.78 -0.01 (-0.73%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.13 +0.27 (+2.28%)
Closing price 05/13/2025 04:00 PM Eastern
Extended Trading
$12.53 +0.40 (+3.30%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.01 -0.03 (-0.99%)
Closing price 05/13/2025 04:00 PM Eastern
Extended Trading
$3.00 0.00 (-0.17%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Proteostasis Therapeutics stock logo

Proteostasis Therapeutics NASDAQ:PTI

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.